Having trouble accessing articles? Reset your cache.

SNS01-T: Phase Ib/IIa amended

Senesco said it amended an open-label, dose-escalation, U.S. Phase Ib/IIa trial of twice-weekly IV

Read the full 141 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE